Taysha completes dosing in REVEAL pivotal trial of TSHA-102 for Rett syndrome

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA

0.00
  • Taysha Gene Therapies completed dosing in its REVEAL pivotal trial of TSHA-102 for Rett syndrome, enrolling 17 patients.
  • Longer-term results from the earlier REVEAL Phase 1/2 Part A cohort were already presented, showing sustained functional improvements across patients.
  • No treatment-related serious safety issues were reported across REVEAL studies through the June 2026 cutoff, supporting the program’s risk profile.
  • Topline results from the pivotal trial’s 6-month interim analysis will be presented in 1H 2027, alongside FDA feedback on a potential BLA pathway.
  • An additional safety-focused ASPIRE study in younger patients remains on track to finish dosing in July 2026 to support a broader label strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220800PRIMZONEFULLFEED9750124) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.